SCHEMBL711037

SCHEMBL711037

CC(C)Oc1cc(OCc2ccccc2)cc(-c2nc3cc(-c4cccnc4)cnc3[nH]2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.44
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
STAT1 P42224 1/20 0.41
GRM5 P41594 1/20 0.41
GCK P35557 2/20 0.41
MAPK1 P28482 1/20 0.39
SMPD1 P17405 1/20 0.38
CYP11B1 P15538 3/20 0.37
CYP11B2 P19099 2/20 0.37
KIT P10721 1/20 0.37
CYP19A1 P11511 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710173 0.93 GCK (0.44) PRMT5MAPTKDM4ENPC1ALDH1A1
SCHEMBL711343 0.87 GCK (0.41) GCKGRIN1GRIN2BMCL1
SCHEMBL2668116 0.87 GCK (0.44) KDM4ENPC1ALDH1A1HPGDRAB9A
SCHEMBL709496 0.86 PRMT5 (0.44) PRMT5GCKCYP3A4MCL1CHEK2
SCHEMBL719830 0.86 MCL1 (0.43) PRMT5MAPTKDM4ENPC1ALDH1A1
SCHEMBL711177 0.86 PRMT5 (0.42) PRMT5MAPTKDM4ENPC1ALDH1A1
SCHEMBL10206659 0.85 DHODH (0.41) PRMT5KDM4ENPC1ALDH1A1HPGD
SCHEMBL710843 0.84 GCK (0.41) PRMT5GCKGRIN1GRIN2BMCL1
SCHEMBL711270 0.84 GRIN1 (0.44) GCKGRIN1GRIN2B
SCHEMBL710664 0.84 DHODH (0.46) PRMT5MAPTKDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK PRMT5 2373/4885MAPT 3003/4885KDM4E 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.